1
项与 重组人凝血因子Ⅷ脂质体(Ascension Healthcare) 相关的临床试验A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip Administered Intravenously to Severe Haemophilia A Patients With and Without Inhibitors to FVIII
The purpose of this study is to demonstrate that PEGylated liposomes (PEGLip) can shield FVIII from the immune system and inhibitors, and therefore provide a prophylactic FVIII replacement therapy for patients with inhibitors to FVIII.
100 项与 重组人凝血因子Ⅷ脂质体(Ascension Healthcare) 相关的临床结果
100 项与 重组人凝血因子Ⅷ脂质体(Ascension Healthcare) 相关的转化医学
100 项与 重组人凝血因子Ⅷ脂质体(Ascension Healthcare) 相关的专利(医药)
100 项与 重组人凝血因子Ⅷ脂质体(Ascension Healthcare) 相关的药物交易